Specialties

Reclassification of AML Subtypes and Risk in Light of ICC and ELN2022

17 September 2024 13:51

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Second-line therapy for multiple myeloma: Where we are now?

Presented By

Dr Francesca Gay, University of Torino, Italy

Conference

EMN 2024

23 April 2024 11:56

The state of toxicities for immunotherapy for multiple myeloma

Presented By

Dr Alfred Garfall, University of Pennsylvania, PA, USA

Conference

EMN 2024

23 April 2024 11:39

Early multiple myeloma: where are immunotherapies headed?

Presented By

Dr Elias K. Mai, University Hospital Heidelberg, Germany

Conference

EMN 2024

23 April 2024 11:34

How does resistance arise for immunotherapy in relapsed/refractory multiple myeloma?

Presented By

Dr Nizar Bahlis, University of Calgary, Canada

Conference

EMN2024

23 April 2024 11:27

Functional imaging to complement bone marrow MRD in multiple myeloma

Presented By

Dr Elena Zamagni, Bologna University, Italy

Conference

EMN 2024

22 April 2024 13:04

Mass spectrometry detection of MRD for patients with multiple myeloma

Presented By

Dr Joannes F. M. Jacobs, Radboud University Medical Center, the Netherlands

Conference

EMN 2024

22 April 2024 13:02

Is MRD testing ready for prime time in multiple myeloma?

Presented By

Prof. Edward A. Stadtmauer, University of Pennsylvania, PA, USA

Conference

EMN 2024

22 April 2024 12:59

Managing transplant-ineligible elderly and frail patients with multiple myeloma

Presented By

Dr Salomon Manier, University of Lille, France

Conference

EMN 2024

22 April 2024 12:57

Treatment should be tailored to frailty status in patients with transplant-ineligible newly diagnosed multiple myeloma

Presented By

Dr Sara Bringhen, University of Torino, Italy

Conference

EMN 2024

22 April 2024 12:53

Interview: Advancing Myeloma Care

Expert

Prof. Monique Minnema, UMC Utrecht, the Netherlands

19 March 2024 14:42

Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

19 March 2024 14:29

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By

Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By

Dr Moritz Fürstenau, University of Cologne, Germany

Trial

Phase 2, CLL2-BAAG

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:01

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

Interview: Sandwich treatment model shows promise for mantle cell lymphoma

Expert

Dr Eliza Hawkes, Olivia Newton-John Cancer Wellness & Research Centre, Australia

Trial

Phase 2, WAMM

Conference

ASH 2023

4 January 2024 14:30

Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN

Expert

Prof. Jeff Sharman , The US Oncology Network and Willamette Valley Cancer Institute, Oregon, USA

Trial

Phase 3, ELEVATE-TN

Conference

ASH 2023

18 December 2023 18:14

How should multiple myeloma research change in a patient-oriented world?

19 September 2023 13:16

Overweight/obese BMI linked to worse survival in young people with leukemia

19 September 2023 13:11

How can we further improve lymphoma care?

Expert

Lorna Warwick, Lymphoma Coalition

14 September 2023 09:16

What every doctor should know about CLL in today’s treatment landscape

Expert

Dr Jennifer Brown, Dana-Farber Cancer Institute & Harvard University, MA, USA

21 August 2023 14:58

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Radiotherapy or not in patients with PMBCL after immunochemotherapy?

Presented By

Dr Maurizio Martelli, University Sapienza Roma, Italy

Trial

IELSG37

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:16

Zandelisib promising in relapsed/refractory indolent B-cell NHL

Presented By

Dr Takahiro Kumode, Kindai University, Japan

Trial

Phase 2, MIRAGE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:05

Promising data for epcoritamab plus R-CHOP in untreated DLBCL

Presented By

Dr Michael Clausen, Lillebaelt Hospital, Denmark

Trial

Phase 1/2, EPCORETM NHL-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:43

Can we combine teclistamab and nirogacestat for the treatment of RRMM?

Presented By

Dr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA

Trial

Phase 1, MajesTEC-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:21

Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM

Presented By

Prof. Sebastian Grosicki, Medical University of Silesia, Poland

Trial

Phase 1/2, DREAMM 5

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:15

CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM

Presented By

Dr Hermann Einsele, University of Würzburg, Germany

Trial

Phase 3, CARTITUDE-4

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:08

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By

Prof. Alex Herrera, City of Hope Medical Center, CA, USA

Trial

Phase 3, SWOG S1826

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:38

ASCO 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO 2023

26 June 2023 03:07

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By

Dr Emily Liang, University of Washington, WA, USA

Trial

Phase 2

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:31

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

Ide-cel superior to standard therapies in triple-class exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:48

ASCT or CAR T cell as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Trial

Phase 3, CARTITUDE-6

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:23

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DETERMINATION

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:14

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:02

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By

Prof. Olaf Penack, Charité University Hospital of Berlin, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:55

Tacrolimus versus cyclosporin A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:48

Promising novel target identified for AML

Presented By

Prof. Edmund Waller, Emory University, GA, USA

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:42

Statins associated with reduced heart dysfunction from anthracyclines

Presented By

Prof. Tomas Neilan, Massachusetts General Hospital, MA, USA

Trial

Phase 2, STOP-CA

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:58

Dexamethasone and Pomalidomide in combination with Elotuzumab for RRMM

Trial

Phase 2, ELOQUENT-3

17 April 2023 14:28

CAR T cells rise to the front in multiple myeloma

Expert

Dr Sergio Giralt, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KarMMa-3

17 April 2023 12:45

Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma 

Presented By

Prof. Martin Dreyling, University Hospital Munich, Germany

Trial

Phase 3, Triangle

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:39

High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma 

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:37

Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Presented By

Prof. Won-Seog Kim, Samsung Medical Center, South Korea

Trial

Phase 2, ELM-2 trial

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:30

Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma

Presented By

Dr Yago Nieto, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:27

CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL 

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:23

Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data 

Presented By

Prof. Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1/2, MonumenTAL-1

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:19

Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial 

Presented By

Prof. Nizar Bahlis, University of Calgary, Canada

Trial

Phase 2, MagnetisMM-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:09

Deep and durable responses for quadruple therapy in smouldering MM 

Presented By

Prof. Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, ASCENT

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:04

Ultra-sensitive MRD assessment in MM with BloodFlow

Presented By

Dr Laura Notarfranchi, University of Parma, Italy

Trial

Phase 3, GEM2014MAIN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:55

CAR-Hematotox score proves useful in relapsed/refractory MM

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:52

Head-to-head: VMP versus Rd in transplant-ineligible MM

Presented By

Dr Sara Bringhen, Università degli Studi di Torino, Italy

Trial

Phase 4, REAL-MM

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:47

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By

Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA

Trial

Phase 3, ALPINE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:40

Ibrutinib plus venetoclax displays long-term benefits in CLL 

Presented By

Prof. John Allan, Weill Cornell Medicine, NY, USA

Trial

Phase 2, CAPTIVATE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:28

Excellent results for triplet regimen in FLT3-mutated AML 

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML 

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? 

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL 

Presented By

Prof. Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN-E1910 NCTN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:07